Harping on the past performance of other, totally unrelated, companies adds no value to this discussion. The old adage that “past performance is no guarantee of future results,” is so very true in this case. OXBO has it’s own unique circumstances, and cannot be compared with other companies. If OXBO up-lists, and then hits with oxycyte the shareholdes will be rewarded. IMO, if Oxycyte achieves some major milestones while up-listed the rewards will be far greater then they would be on the OTCBB.